- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Coalition Offers Broad Framework to Improve Kidney Care
A coalition of patient advocates, dialysis-care providers and manufacturers today will unveil a comprehensive new framework for kidney care across the country that identifies four goals: improve survival, reduce hospitalizations, improve health-related quality of life, and improve patient experience with care.
A coalition of patient advocates, dialysis-care providers and manufacturers today will unveil a comprehensive new framework for kidney care across the country that identifies four goals: improve survival, reduce hospitalizations, improve health-related quality of life, and improve patient experience with care.
Kidney Care Partners—established in 2003 to improve care for people with chronic kidney disease—will release A Strategic Blueprint for Advancing Kidney Care Quality (PDF), after more than a year of work on the ambitious plan. The blueprint will also be the focus of a webinar on world kidney day on March 13.
The blueprint cites data from the U.S. Renal Data System that roughly 615,000 adults and about 9,000 children lived with end-stage renal disease in 2011 and required either dialysis or a transplant to survive. While there have been recent improvements in kidney care, members of Kidney Care Partners thought more needed to be done. At a meeting roughly two years ago, members discussed ways to drive quality in this segment and determined they needed to step back and establish priorities.
Read the full story here: http://bit.ly/1fCi1OL
Source: Modern Healthcare
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
